

# EL Reumatólogo

EL REUMATÓLOGO Nº 9

## ARTÍCULO: EFECTO DE LA PANDEMIA POR COVID-19 EN LAS ENFERMEDADES INMUNOMEDIADAS

Dr. Diego Benavent Núñez.

Servicio de Reumatología. Hospital Universitario La Paz. Madrid

### BIBLIOGRAFÍA

1. Favalli EG, Ingegnoli F, Lucia O De, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! *Autoimmun Rev* 2020.
2. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis* 2020.
3. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? *Ann Rheum Dis* 2020.
4. Cron RQ, Chatham WW. The Rheumatologist's Role in COVID-19. *J Rheumatol* 2020.
5. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19. *Ann Rheum Dis* 2020.
6. Gianfrancesco M, Hyrich KL, Hyrich KL, Al-Adely S, Al-Adely S, Carmona L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020.
7. Ramiro S, Mostard RLM, Magro-Checa C, Dongen CMP Van, Dormans T, Buijs J, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: Results of the CHIC study. *Ann Rheum Dis* 2020.
8. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, R LM. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N Engl J Med* 2020.
9. Landewé RBM, Landewé RBM, MacHado PM, Kroon F, Bijlsma HWJ, Burmester GR, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. *Ann Rheum Dis* 2020.
10. Akhil Sood, Arbi Galestianian, Vijaya Murthy EG and MR. Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study - ACR Meeting Abstracts. Available at: <https://acrabstracts.org/abstract/assessment-of-the-covid-19-pandemic-from-the-perspective-of-people-with-rheumatic-musculoskeletal-diseases-in-europe-preliminary-results-from-the-reumavid-study/>. Accessed December 15, 2020.
11. Marco Garrido-Cumbrera, Helena Marzo-Ortega, José Correa-Fernández, Sergio Sanz-Gomez LC and VN-C. COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review - ACR Meeting Abstracts. Available at: <https://acrabstracts.org/abstract/covid-19-infection-among-patients-with-rheumatic-disease-on-biologic-targeted-therapies-a-systematic-review/>. Accessed December 15, 2020.
12. Rubin EJ, Longo DL. SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention. *N Engl J Med* 2020;NEJMe2034717. Available at: <http://www.nejm.org/doi/10.1056/NEJMe2034717>. Accessed December 15, 2020.